Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Methotrexate,MTX2023-001,2023,USA,MDV,350,62,45,55,27.5,32,85,12,20,35,30,15,60,25,10,5,25,35,25,18,7,3,9,4,22,48,35,CMF,AC,CMF,MTX/5-FU,15,10,8,20,40,55,15,45,40,60,2
Methotrexate,MTX2022-002,2022,Canada,Claim Database,420,68,52,48,28.1,28,78,15,18,32,35,15,55,30,10,5,22,38,22,20,8,4,10,5,25,50,40,AC,FEC,MTX/5-FU,AC,12,15,10,25,45,60,10,50,40,65,3
Methotrexate,MTX2024-003,2024,UK,MDV,280,70,48,52,26.9,35,80,10,22,38,25,15,65,20,10,5,28,32,20,15,6,2,8,3,20,45,30,FEC,CMF,CMF,MTX,10,12,5,18,38,50,20,40,40,55,2.5
